Rare diseases
Investigational molecules
Locations
Back to Czechia21 clinical trials in Louny, Czechia. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in CzechiaKlinickeTesty.cz(opens in a new tab)Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease
CzechiaStudy of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it
CzechiaA study of the safety and efficacy of AC01 in patients with heart failure with reduced ejection fraction
CzechiaEffect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)
CzechiaEvaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function
CzechiaCzechiaStudy on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems
CzechiaEvaluating the efficacy and safety of CRD-4730 in patients with heart failure with reduced ejection fraction
CzechiaStudy of ISIS 678354 for Patients with Severe High Triglycerides
CzechiaStudy on the Effects of Pelacarsen on Heart Disease in Patients with Cardiovascular Conditions
CzechiaStudy of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke
CzechiaStudy of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease
CzechiaThe busiest research cities in the country
What the registry says about research in the country
Innovative research focusing on cardiovascular disease treatments, including studies of novel therapeutics for reducing major adverse cardiovascular events and improving patient outcomes.
Advanced clinical investigations targeting specific cardiovascular biomarkers and their role in disease progression.
Comprehensive studies examining new treatments for chronic heart failure, with particular attention to patients with reduced ejection fraction and kidney function impairment.
Innovative approaches to managing heart failure symptoms and improving quality of life.
Research initiatives addressing dyslipidemia and severe hypertriglyceridemia, investigating new therapeutic approaches for managing blood lipid levels.
Cutting-edge treatments targeting metabolic disorders and their cardiovascular complications.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
